Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme

Trial Profile

Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2018

At a glance

  • Drugs H 1PV (Primary) ; H 1PV (Primary) ; H 1PV (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oryx GmbH & Co
  • Most Recent Events

    • 16 May 2018 Results presented in the GmbH & Co media release.
    • 16 May 2018 According to an Oryx GmbH & Co media release, data from this trial will be presented at the 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) (May 20118).
    • 06 Nov 2017 According to an Oryx GmbH & Co media release, results from this trial will be published in the peer-reviewed medical journal, Molecular Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top